| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.6 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |